Patents by Inventor Samia Mankarious

Samia Mankarious has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210177976
    Abstract: Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° C./60% relative humidity (RH) and 40° C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40° C./75% RH or 25° C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8° C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity.
    Type: Application
    Filed: July 28, 2020
    Publication date: June 17, 2021
    Inventors: Samia Mankarious, Michael J. Griffith
  • Publication number: 20190167797
    Abstract: Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° C./60% relative humidity (RH) and 40° C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40° C./75% RH or 25° C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8° C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity.
    Type: Application
    Filed: July 6, 2018
    Publication date: June 6, 2019
    Inventors: Samia Mankarious, Michael J. Griffith
  • Publication number: 20160287709
    Abstract: Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° C./60% relative humidity (RH) and 40° C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40° C./75% RH or 25° C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8° C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 6, 2016
    Inventors: Samia Mankarious, Michael J. Griffith
  • Publication number: 20100316625
    Abstract: Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° C./60% relative humidity (RH) and 40° C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40° C./75% RH or 25° C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8° C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity.
    Type: Application
    Filed: December 16, 2008
    Publication date: December 16, 2010
    Applicant: Inspiration Biopharmaceuticals, Inc.
    Inventors: Samia Mankarious, Michael J. Griffith
  • Patent number: 4439421
    Abstract: Gamma globulin concentrates are stabilized against anticomplement activity generation during lyophilization by inclusion in the concentrate of a physiologically acceptable, substantially nonsurface-active hydrophilic macromolecule. The improved concentrates may be safely administered to patients. The main additives to the gamma globulin are a substantially nonsurface-active hydrophilic macromolecule, a protein and a polyol.
    Type: Grant
    Filed: August 30, 1982
    Date of Patent: March 27, 1984
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: John A. Hooper, Samia Mankarious, Catherine R. Liu-Rash